BofA Securities downgrades ProKidney stock to Underperform on reduced sales outlook

Published 30/06/2025, 12:02
BofA Securities downgrades ProKidney stock to Underperform on reduced sales outlook

Investing.com - BofA Securities downgraded ProKidney Corp. (NASDAQ:PROK) from Neutral to Underperform on Monday, while significantly reducing its price target from $3.00 to $1.00 per share. According to InvestingPro data, the company’s stock has already declined over 70% in the past year, with a current market capitalization of approximately $196 million.

The downgrade reflects BofA’s more conservative peak sales outlook for REACT, ProKidney’s sole product candidate being developed for the treatment of diabetic chronic kidney disease. The revised outlook follows recent discussions with nephrology experts that suggested changes in the competitive landscape.

BofA now projects peak sales of $900 million for REACT, down from its previous estimate of $1.8 billion, citing the need for more segmentation-related adjustments that reduce the total addressable market. The firm maintains its view that REACT remains a high-risk program with a 40% probability of success.

The investment bank expressed caution about ProKidney’s ability to materially advance the timeline for Phase 3 data, which is currently expected in the third quarter of 2027. BofA’s revised price target is based on a discounted cash flow analysis reflecting the reduced sales forecast.

BofA stated that the risk/reward profile for ProKidney now skews to the downside, citing a financing overhang and limited value-inflection catalysts in the near term. Despite these concerns, InvestingPro data indicates the company maintains a strong liquidity position with a current ratio of 11, and its next earnings report is scheduled for August 7, 2025. Get more detailed insights and 13 additional ProTips with InvestingPro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.